News | Cath Lab | June 22, 2017

Vascular Solutions Recalls Venture Catheters That May Split or Separate During Use

FDA identified this as a Class 1 recall due to the possibility of components embolizing

The Vascular Solutions Venture catheters were recalled due to tip separation

June 22, 2017 — The U.S. Food and Drug Administration (FDA) has identified Vascular Solutions’ recent recall of its Venture catheters as a Class I recall, it announced this week. This is the most serious type of recall, because the FDA said use of these devices may cause serious injuries or death.

Vascular Solutions initiated a voluntary recall of the guidewires April 25, 2017. The company said there is a risk of the catheter tip splitting or separating during use. Excess material at the tip of the catheter may separate and could embolize into the patient's bloodstream. This can result in serious adverse health consequences such as the development of blood clots, embolism of the excess material to vital organs, or death.

Recall is for Venture RX Catheter (Model 5820), Venture OTW (Model 5821) and Venture CS  Catheter (Model 5822). These devices were distribution between May 7, 2015 to April 19, 2017, and manufactured between May 7, 2015 to March 31, 2017. The recall includes 7,054 nationwide in the U.S.

The Venture catheter is intended for directing, steering, controlling and supporting a guidewire to access veins and arteries in the arms, legs, hands, feet, and heart muscle (myocardium). Certain models may also administer saline fluids or drugs into blood vessels.

The company sent an urgent medical device recall letter to all affected customers. The letter asked distributors and customers to identify and remove any affected Venture catheters from inventory and quarantine. This includes completing a field safety notice and a customer inventory form. After all the affected catheters are returned, customers are asked to complete the Vascular Solutions Inc. Distributor Inventory Form, and return it via email to [email protected] Upon receipt of the form, Vascular Solutions' customer service department will provide a return authorization number and arrange for return of affected Venture catheters. A credit will be offered after affected devices have been returned, the company said.

Healthcare professionals and consumers may contact Vascular Solutions at (888) 240-6001 Monday through Friday, between the hours of 8 a.m. and 5 p.m. Central Time, or by e-mail at [email protected] with any questions related to this recall.

For a complete list of recalled product codes and lot numbers go to www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm564092.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Related Content:

VIDEO: Basics of Interventional Guidewire Design and Function

Understanding the Design and Function of Guidewire Technology

The Basics of Guide Wire Technology

 

Related Content

Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...
News | Cath Lab | December 18, 2019
December 18, 2019 — Cook Medical initiated a recall of its CrossCath Support Catheters in November, which the U.S.
Gallery | Cath Lab | October 31, 2019
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Overlay Init